Cholinesterase inhibitors (ChEIs) are effective in improving cognition and behavior in patients affected by Alzheimer’s disease (AD) as well as by Lewy bodies dementia (DLB). The authors compared the effect of rivastigmine in the treatment of cognitive impairment and behavioral and psychological symptoms of dementia (BPSD) in 30 AD and in 30 DLB patients. At baseline, DLB compared to AD patients showed a greater number of extrapyramidal symptoms (P < .005) and were similar regarding cognitive symptoms and BPSD. After treatment, both groups showed a comparable cognitive and psycho-behavioral improvement. A significant difference between AD and DLB patients was found for hallucinations (P < .002). Rivastigmine produces comparable cognitive benefits in patients with DLB and AD and also a significant improvement of behavioral disorders. These findings support the view that ChEIs should be considered a first-line treatment of the cognitive and psycho-behavioral symptoms of both AD and DLB.
McKhann G, Drachman D, Folstein M, et al.Clinical diagnosis of Alzheimer’s disease: report of the NINCDSADRDA work group. Neurology.1984;34: 939-944.
2.
McKeith IG, Galasko D, Kosaka K, et al.Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996; 47: 1113-1124.
3.
Perry EK, Hroutunian V, Davis KL, et al.Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer’s disease. Neuroreport. 1994;5: 747-749.
4.
Hamilton RL.Lewy bodies in Alzheimer disease: a neuropathologic review. Brain Pathol. 2000;10: 378-384.
5.
Perry EK, Perry RH.Altered consciousness and transmitter signalling in Lewy body dementia. In: Perry R, McKeith I, Perry E, eds. Dementia With Lewy Bodies. New York, NY: Cambridge University Press; 1996:397-413.
6.
Liberini P, Valerio A, Memo M, Spano PF.Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer’s disease? Trends Pharmacol Sci. 1996;17: 155-160.
7.
Rogers SL, Farlow MR, Doody RS, et al.A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology. 1998;50: 136-145.
8.
Corey-Bloom J, Anand R, Veach J, et al.A randomized trial evaluating the efficacy and safety of ENA 713 (rivastig-mine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol. 1998;1: 55-65.
9.
Tariot PN, Solomon PR, Morris JC, et al.A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54: 2269-2276.
10.
Grace J, Daniel S, Stevens T, et al.Long-term use of rivastigmine in patients with dementia Lewy bodies: an open-label trial. Int Psychogeriatr. 2001;13: 199-205.
11.
Maclean LE, Collins CC, Byrne EJ.Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. Int Psychogeriatr. 2001;13: 277-288.
12.
McKeith IG, Del Ser T, Spano P, et al.Efficacy of rivastigmine in dementia with Lewy bodies: a randomised double blind placebo controlled international study. Lancet. 2000;356: 2031-2036.
13.
Wesnes KA, McKeith IG, Ferrara R, et al.Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord. 2002;13: 183-192.
14.
Pakrasi S, Mukaetova-Ladinska EB, McKeith I, et al.Clinical predictors of response to acetyl cholinesterase inhibitors: experience from routine clinical use in Newcastle. Int J Geriatr Psychiatry. 2003;18: 879-886.
15.
Gabelli C.Rivastigmine: an update on therapeutic efficacy in Alzheimer’s disease and other conditions. Curr Med Res Opin. 2003;19: 69-82.
16.
Samuel W, Calgiuri M, Galasko D, et al.Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry. 2000;15: 794-802.
17.
Hughes CP, Berg L, Danziger WL, et al.A new clinical scale for the staging of dementia. Br J Psychiatry. 1982; 140: 566-572.
18.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed.Washington, DC: American Psychiatric Association; 1994.
19.
Lawton MP, Brody EM.Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9: 179-186.
20.
Mahoney FI, Barthel DW.Functional evaluation: the Barthel Index. Md State Med J. 1965;14: 61-65.
21.
Folstein MF, Folstein FE, McHugh PR.Mini-Mental State: a practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res. 1975;12: 189-201.
22.
Cummings JL, Mega M, Gray K, et al.The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44: 2308-2314.
23.
Sheikh JI, Yesavage JA.Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: Brink TL, ed. Clinical Gerontology: A Guide to Assessment and Intervention. New York, NY: Haworth Press; 1986:165-173.
24.
Fahn S, Elton RL.Members of the UPDRS development committee: unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson’s Disease. Florham Park, NJ: MacMillan Healthcare Information; 1987:153-304.
25.
Statistical Package for the Social Sciences for Windows [computer program]. Release 11.5.1 (Italian version). Chicago, Ill: SPSS; 2002.
26.
Barak Y, Bodner E, Zemishlani H, et al.Donepezil for the treatment of behavioral disturbances in Alzheimer’s disease: a 6-month open trial. Arch Gerontol Geriatr. 2001;33: 237-241.
27.
Gauthier S, Feldman H, Hecker J, et al.Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr. 2002;14: 389-404.
28.
Morris JC, Cyrus PA, Orazem J, et al.Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology. 1998;50: 1222-1230.
29.
Trinh NH, Hoblyn J, Mohanty S, et al.Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289: 210-216.
30.
McKeith IG.Dementia with Lewy bodies. Br J Psychiatry. 2002;180: 144-147.
31.
Tiraboschi P, Hansen LA, Alford M, et al.The decline in synapses and cholinergic activity is asynchronous in Alzheimer’s disease. Neurology. 2000;55: 1278-1283.
32.
Tiraboschi P, Hansen LA, Alford M, et al.Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry. 2002;59: 946-951.
